These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 21473715)
21. Genetic and immune correlates of the HIV infection and vaccine-induced immunity. Foreword. Füst G Vaccine; 2008 Jun; 26(24):2949-50. PubMed ID: 18321613 [No Abstract] [Full Text] [Related]
22. Current world literature. Curr Opin HIV AIDS; 2013 Mar; 8(2):155-62. PubMed ID: 23380657 [No Abstract] [Full Text] [Related]
24. Improving defences at the portal of HIV entry: mucosal and innate immunity. Shattock RJ; Haynes BF; Pulendran B; Flores J; Esparza J; PLoS Med; 2008 Apr; 5(4):e81. PubMed ID: 18384232 [TBL] [Abstract][Full Text] [Related]
25. Mucosal immunity and HIV/AIDS vaccines. Report of an International Workshop, 28-30 October 2007. Girard MP; Bansal GP; Pedroza-Martins L; Dodet B; Mehra V; Schito M; Mathieson B; Delfraissy JF; Bradac J Vaccine; 2008 Jul; 26(32):3969-77. PubMed ID: 18513838 [TBL] [Abstract][Full Text] [Related]
26. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem. Koff WC Vaccine; 2012 Jun; 30(29):4310-5. PubMed ID: 22100891 [TBL] [Abstract][Full Text] [Related]
27. Innate immunity in HIV infection and implications for vaccine design: a summary of the workshop held at the National Institute of Allergy and Infectious Diseases, Bethesda on February 25-26, 2010. Bansal GP; Leitner WW Vaccine; 2010 Dec; 28(52):8229-35. PubMed ID: 21073990 [TBL] [Abstract][Full Text] [Related]
28. Development of prophylactic AIDS vaccines: the current state of affairs. Hanke T Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467 [TBL] [Abstract][Full Text] [Related]
29. Editorial: Fc receptor-mediated effector functions in the humoral control of HIV-1 infection. DeVico A Curr HIV Res; 2013 Jul; 11(5):343-4. PubMed ID: 24191941 [No Abstract] [Full Text] [Related]
30. Broadly neutralizing antibodies against HIV-1: templates for a vaccine. van Gils MJ; Sanders RW Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615 [TBL] [Abstract][Full Text] [Related]
32. Support for the RV144 HIV vaccine trial. Belshe R; Franchini G; Girard MP; Gotch F; Kaleebu P; Marthas ML; McChesney MB; McCullough R; Mhalu F; Salmon-Ceron D; Sekaly RP; van Rompay K; Verrier B; Wahren B; Weissenbacher M Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15247455 [No Abstract] [Full Text] [Related]
33. Species-specific CD1-restricted innate immunity for the development of HIV vaccine. Takahashi H Vaccine; 2010 May; 28 Suppl 2():B3-7. PubMed ID: 20510740 [TBL] [Abstract][Full Text] [Related]
34. Grim news for vaccine. AIDS Patient Care STDS; 2002 Oct; 16(10):513-4. PubMed ID: 12442739 [No Abstract] [Full Text] [Related]
35. Humoral immunity to HIV, SIV, and SHIV. Haigwood NL; Zolla-Pazner S AIDS; 1998; 12 Suppl A():S121-32. PubMed ID: 9632993 [No Abstract] [Full Text] [Related]
36. HIV vaccine: hopes and hurdles. Chhatbar C; Mishra R; Kumar A; Singh SK Drug Discov Today; 2011 Nov; 16(21-22):948-56. PubMed ID: 21889604 [TBL] [Abstract][Full Text] [Related]